Sterling Capital Management’s Standard BioTools LAB Stock Holding History

Sterling Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.76K	Sell	9,526 -7,715	-45%	-$9.34K	﹤0.01%	2446
2025 Q4	$22.1K	Sell	17,241 -3,413	-17%	-$4.58K	﹤0.01%	2175
2025 Q3	$26.9K	Buy	20,654 +12,572	+156%	+$16.5K	﹤0.01%	2002
2025 Q2	$9.7K	Buy	8,082 +4,067	+101%	+$4.51K	﹤0.01%	2150
2025 Q1	$4.34K	Sell	4,015 -3,377	-46%	-$4.74K	﹤0.01%	2242
2024 Q4	$12.9K	Buy	7,392 +6,496	+725%	+$12.1K	﹤0.01%	2046
2024 Q3	$1.73K	Buy	+896	New	+$1.75K	﹤0.01%	2250
2015 Q4	–	Sell	-27,673	Closed	-$224K	–	1012
2015 Q3	$224K	Buy	27,673 +10,013	+57%	+$158K	﹤0.01%	905
2015 Q2	$427K	Buy	+17,660	New	+$557K	﹤0.01%	744

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Sterling Capital Management's LAB Position: Q1 2026 in Review

Sterling Capital Management reduced its Standard BioTools (LAB) stake by 45% in Q1 2026, selling an estimated $9.34K and leaving 9,526 shares worth $8.76K. The position accounts for ﹤0.01% of the portfolio, ranked #2446.

Sterling Capital Management first reported a position in LAB in Q2 2015 and has held it in 9 quarters since. The position peaked at $427K in Q2 2015. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

Sterling Capital Management held 9,526 shares of Standard BioTools worth $8.76K as of Q1 2026.
Sterling Capital Management sold 7,715 Standard BioTools shares in Q1 2026, an estimated $9.34K.
Standard BioTools made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2446 holding.
Sterling Capital Management first reported a position in Standard BioTools in Q2 2015 and has held it in 9 quarters since.
Sterling Capital Management's Standard BioTools position peaked at $427K in Q2 2015.
155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.